Karl Storz and Photocure to
collaborate on commercializing the high-definition system
OSLO, Norway, Sept. 28, 2022 /PRNewswire/ -- Photocure ASA
(OSE: PHO), the Bladder Cancer Company, announces the commercial
availability of Karl Storz's New
Blue Light equipment powered by Saphira™ in the U.S. As part of the
rollout, Karl Storz plans to host a
Virtual Launch event for the medical community streamed from its
El Segundo, California office
where Sia Daneshmand M.D. and
Kristin Scarpato M.D. M.P.H. will discuss the clinical benefits of
using BLC® with Cysview® for NBMIC*,
while sharing their perspectives on the advantages that the New
Blue Light system provides over the original system for TURBT**.
The Virtual Launch event is scheduled to take place on October 13, 2022 at 4:00pm
Pacific Time.
"We are pleased to share that Karl
Storz has begun filling Obsolescence Protection Program
(OPP) orders for customers who purchased New Blue Light system
upgrades last year," said Geoff
Coy, Vice President and General Manager, North America. "Orders for the new Saphira
system appear to be outpacing orders from the past signaling pent
up demand for the advanced technology, and we expect to begin
filling new account orders in the fourth quarter. Given the strong
demand, we continue to believe that BLC is on its way to becoming
the standard of care for endoscopic visualization of bladder
cancer."
"Uro-oncologists and their staff have expressed a strong
desire to have the new Blue Light system at their hospitals, and
the upcoming Virtual Launch Event is an opportunity to showcase the
system's benefits and broaden awareness of BLC in the market,"
said Ken Pugh, Head of North America
Marketing and Alliance Management. "Accordingly, we are working
diligently with our partners to ensure that all customers who want
The New Blue Light, have it for all appropriate patients with
NMIBC."
Dr. Sia Daneshmand, M.D., is
Professor of Urology with Clinical Scholar designation and serves
as director of clinical research as well as the urologic oncology
(SUO) fellowship director at the University of
Southern California (USC) in
Los Angeles.
Dr. Kristin Scarpato, M.D.,
M.P.H., is Associate Professor Department of Urology residency
program director and vice chair of education for the Department of
Urology, Division of Urologic Oncology at Vanderbilt University Medical Center in
Tennessee.
*NMIBC: Non-muscle invasive bladder cancer
**TURBT: Transurethral resection of bladder tumor
Note to editors:
Hexvix®/Cysview® and BLC® are
registered trademarks of Photocure ASA. IMAGE1 S™ and Saphira™ are
registered trademarks of KARL STORZ Endoscopy.
This press release may contain product details and information
which are not valid, or a product that is not accessible, in your
country. Please be aware that Photocure does not take any
responsibility for accessing such information, which may not comply
with any legal process, regulation, registration, or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer
worldwide – the 5th most common in men – with
1 720 000 prevalent cases (5-year prevalence
rate)1a, 573 000 new cases and more than
200 000 deaths in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate with up to 61% in
year one and up to 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all BC cases and include the
subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3 and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b)
incidence/mortality by population. Available at:
https://gco.iarc.fr/today, accessed [January
2022]
2 Babjuk M, et al. Eur Urol. 2019; 76(5):
639-657
3 Sievert KD et al. World J Urol
2009;27:295–300
4 Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix/Cysview is a drug that preferentially accumulates in
cancer cells in the bladder, making them glow bright pink during
Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview,
compared to standard white light cystoscopy alone, improves the
detection of tumors and leads to more complete resection, fewer
residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly
in the U.S. and Europe and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Chile, Australia, New
Zealand and Israel. Please
refer to https://photocure.com/partners/our-partners for
further information on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/photocure-announces-the-commercial-availability-of-karl-storz-s-new-blue-light-system-in-the-u-s-,c3637616
The following files are available for download:
|
https://mb.cision.com/Main/17498/3637616/1631581.pdf
|
Release
|
View original
content:https://www.prnewswire.co.uk/news-releases/photocure-announces-the-commercial-availability-of-karl-storzs-new-blue-light-system-in-the-us-301635128.html